


PHARMACEUTICAL 2022



CUMBERLAND PHARMACEUTICALS SPHARMACEUTICALS INC

Rank 95 of 475





PHARMACEUTICAL 2022



CUMBERLAND PHARMACEUTICALS \$\frac{1}{2} \text{PHARMACEUTICALS}\$ **INC**



Rank 95 of 475

The relative strengths and weaknesses of CUMBERLAND PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CUMBERLAND PHARMACEUTICALS INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 269% points. The greatest weakness of CUMBERLAND PHARMACEUTICALS INC is the variable Other Expenses, reducing the Economic Capital Ratio by 85% points.

The company's Economic Capital Ratio, given in the ranking table, is 51%, being 327% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	45,688
Cost of Goods Sold	8,811
Intangible Assets	24,836
Liabilities, Current	19,279
Liabilities, Non-Current	7,579
Other Assets	13,493
Other Compr. Net Income	0
Other Expenses	19,520
Other Liabilities	15,000
Other Net Income	2,020
Property and Equipment	443
Research and Development	5,684
Revenues	38,172
Selling, General and Administrative Expense	9,780

Output Variable	Value in 1000 USD
Assets	84,460
Liabilities	41,858
Expenses	43,795
Stockholders Equity	42,602
Net Income	-3,603
Comprehensive Net Income	-3,603
Economic Capital Ratio	51%